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Abstract
The emergence of multidrug-resistant bacterial and fungal strains poses a threat to human health 
that requires the design and synthesis of new classes of antimicr obial agents. We evaluated bis(N-
amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones for their antibacterial and antifungal 
activities against panels of Gram-positive/Gram-negative bacteria as well as fungi. We investigated 
their potential to develop resistance against both bacteria and fungi by a multi-step, resistance-
selection method, explored their potential to induce the production of reactive oxygen species, and 
assessed their toxicity. In summary, we found that these compounds exhibited broad-spectrum 
antibacterial and antifungal activities against most of the tested strains with minimum inhibitory 
concentration (MIC) values ranging from <0.5->500 μM against bacteria and 1.0->31.3 μg/mL 
against fungi; and in most cases, they exhibited either superior or similar antimicrobial activity 
compared to those of the standard drugs used in the clinic. We also observed minimal emergence 
of drug resistance to these newly synthesized compounds by bacteria and fungi even after 15 
passages, and we found weak to moderate inhibition of the human Ether-à-go-go-related gene 
(hERG) channel with acceptable IC50 values ranging from 1.12-3.29 μM. Overall, these studies sh 
ow that bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones are potentially 
promising scaffolds for the discovery of novel antibacterial and antifungal agents.
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1. Introduction
The emergence of multidrug-resistant bacteria and fungi as human pathogens warrants a 
continued focus on the development of new pharmacophores for the treatment of these 
devastating and often fatal infections. The rise of multidrug-resistant bacteria, such as 
methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci 
(VRE), adversely affects the efficacy of many known, standard-of-care, antibacterial agents.1 
Evidence of the impact of these multidrug-resistant strains appears in a 2011 report from the 
Centers for Disease Control and Prevention (CDC) that estimates that the national incidence 
of invasive MRSA infections was 80,461 cases and 650 deaths. This mortality rate is among 
the highest recorded for bacterial infections.2 Likewise, listerosis, which is a common 
foodborne illness caused by Listeria monocytogenes, represents a serious illness afflicting 
elderly people, newborns, and those with impaired immune systems. Estimates are that 19% 
of deaths associated with the consumption of contaminated foods in the United States are 
due to L. monocytogenes.3
The incidence of invasive fungal infections is also on the rise due to an increasing population 
of critically ill patients as a result of the human immunodeficiency virus (HIV), systemic 
diseases such as cancer, and the increasing occurrence of organ transplantation.4 The 
National Healthcare Safety Network (NHSN) at the CDC reported that Candida spp. ranked 
fifth amongst hospital-acquired pathogens.5 Candida spp. are reported as the fourth most 
common causative pathogens of nosocomial and of fatal bloodstream infections.6 Eukaryotic 
C. albicans shares a close evolutionary relationship, as well as many cellular mechanisms, 
with their human hosts, and represents challenges for treatment of systemic fungal 
infections. There is a clear need for new antimicrobials that selectively inhibit these 
microorganisms without causing host toxicity.
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Pentamidine represents an archetypical, biscationic antibiotic with a symmetrical structure 
containing two amidinium functional groups separated by a flexible 1,5-diphenoxypentane 
spacer.7 Developed initially as an antiprotozoal agent, pentamidine currently finds 
applications in both the treatment of protozoan diseases, such as Trypanosoma brucei 
gambiense
(West African trypanosomiasis), as well as systemic fungal infections caused by 
Pneumocystis jirovecii, often seen in patients with HIV. Related compounds include 
symmetrical bisamidines, (e.g., furimidazoline),8 developed principally as topoisomerase 
inhibitors for cancer treatment. In addition to these biscationic compounds, other hydrazone-
containing and guanidine-containing molecules possess a range of promising biological 
activities, including antitubercular,9,10 anti-HIV,11,12 anticonvulsant,13 anticancer,14 anti-
inflammatory,15,16 antimalarial,17,18 antibacterial,19,20 and antifungal activities.21,22 
Recently, bis(N-amidinohydrazones) were reported to inhibit the calcium-dependent serine 
endoprotease, furin, which activates immature proteins to their functional, mature forms.23
Inspired by the above successes, we were intrigued by the possibility that biscationic 
pharmacophores in either the bis(N-amidinohydrazones) or the N-(amidino)-N'-aryl-
bishydrazone family with either a flexible or a rigid spacer would offer advantages in terms 
of antibacterial and antifungal activities not found in the flexible bisamidines, as well as in 
the hydrazone- and guanidine-containing molecules currently in the literature. To investigate 
the potential of such compounds, we synthesized nine symmetrical bis(N-
amidinohydrazones) (3A-B and 4A,C-H) and eight asymmetrical N-(amidino)-N'-aryl-
bishydrazones (7Aa-Ag and 8Aa) (Scheme 1). Further, we evaluated the antibacterial and 
antifungal activities of these novel compounds against panels of bacterial strains (four 
Gram-positive, six Gram-negative, and one mycobacterial) and seven Candida albicans 
strains. Because the development of resistance represents a crucial problem in antimicrobial 
drug development, we also established the potential for resistance development by bacteria 
and fungi against these compounds. Additionally, we measured the production of reactive 
oxygen species (ROS) of some of these compounds in yeast cells, determined their in vitro 
cytotoxicity and their affinity for the human Ether-à-go-go-related gene (hERG) potassium 
channel. The combination of testing new antimicrobial agents and early screening for 
resistance and toxicity represents an avenue that may produce pharmacophores of potential 
utility in the treatment of diseases.
2. Results and discussion
2.1. Design and chemical synthesis of biscationic compounds with two chemically 
identical termini
The reported syntheses of biscationic compounds containing two identical termini bearing 
guanidinium, amidinium, or pyridinium groups attached to aryl or alkyl spacers typically 
involved the modification of spacers with termini bearing primary halides, carbonyl, or 
nitrile groups.24-26 Alkylation of α,ω-dihaloalkanes, for example, with 2-aminopyridine led 
to bis(2-aminopyridinium) salts.24 Modification of the nitrile group in 5-(4-
cyanophenyl)furan-2-carboxylic acid and completion of the spacer by linking the 
carboxylate groups led to bisamidinium agents.27 In the same fashion, we modified the 
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carbonyl groups in either bisaldehyde 1 or bisketone 2, which in some cases were in 
regiochemically distinct positions in the spacer (e.g., 1B, 2B, 2H), with N-aminoguanidine 
hydrochloride to obtain the biscationic products 3 and 4, respectively (Scheme 1A).
2.2. Design and chemical synthesis of biscationic compounds with chemically non-
identical termini
Synthetic approaches to bicationic agents with two chemically non-identical termini often 
involved the construction of the spacer as the ultimate step. For example, the coupling of an 
amidino-substituted naphthol with a guanidine-substituted benzoic acid secured biscationic 
esters with an amidinium group at one terminus and a guanidinium group at the other.28 Our 
approach differed from this strategy in that we utilized a stepwise, chemoselective 
modification of bisaldehydes 1 or bisketones 2 in order to arrive at biscationic systems with 
different cationic groups at each terminus. Condensations of one equivalent of N-
aminoguanidine hydrochloride with 1A and 2A led to the efficient production of 
monosubstituted N-amidinohydrazones 5A and 6A, respectively. The hydrochloride salts of 
these monocatioinic products were readily crystallized free from starting materials. The 
subsequent treatment of 5A and 6A with N-arylhydrazines provided the desired, biscationic 
agents 7Aa-Ag and 8Aa, respectively, which we describe as N-(amidino)-N'-aryl-
bishydrazones (Scheme 1B). Cavallini described the monocationic N-amidinohydrazones as 
antibacterial agents some years ago, but the range of organisms and MIC50 values were, in 
general, unimpressive.29
With these first generations of bis(N-amidinohydrazones) 3 and 4 and N-(amidino)-N'-aryl-
bishydrazones 7 and 8 in hand, we aimed to answer the following eight apriori questions in 
terms of structure-activity-relationship (SAR). We included the numbers of the compounds 
used to answer these questions into parentheses following the questions. The eight questions 
are as follows: (i) are linkers comprised of only one aromatic ring sufficient to confer 
antimicrobial activity? (compounds 4G and 4H); (ii) is the presence of methyl groups on the 
carbons alpha to the linker beneficial for antimicrobial activity? (compounds 3A versus 4A, 
and 7Aa versus 8Aa); (iii) how does the substitution pattern of the biphenyl linker affect 
antimicrobial activity? (compounds 3A and 3B); (iv) how does the length of the flexible 
linear alkyl spacer between the two phenyl rings affect antimicrobial activity? (compounds 
4A, 4C, and 4D); (v) is the introduction of rigidity in the linker beneficial for antimicrobial 
activity? (compound 4C versus 4F); (vi) is the presence of an oxygen atom in the linker 
beneficial for antimicrobial activity? (compound 4C versus 4E); (vii) how does the identity 
of the substituent, when located at the same position on the aryl ring of the side chain, affect 
antimicrobial activity? (compounds 7Aa versus 7Ab, 7Ac versus 7Ad versus 7Ae, and 7Af 
versus 7Ag); and finally, (viii) how does the substitution pattern of the aryl ring (ortho 
versus para-monosubstituted versus ortho,para-disubstituted) affect antimicrobial activity? 
(compounds 7Aa versus 7Ad versus 7Ag).
2.3. Antibacterial activity
To determine if our novel bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-
bishydrazones displayed antibacterial activity, we first evaluated compounds 3A-8Aa against 
a panel of Gram-positive (4 strains), Gram-negative (6 strains), and one mycobacterial strain 
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in a concentration range of 0.5-500 μM (Table 1). We used the aminoglycoside amikacin 
(AMK), the β-lactam ampicillin (AMP), and the fluoroquinolone ofloxacin (OFX) as 
positive controls. In general, the novel compounds displayed excellent (MIC values ≤0.5-7.8 
μM), intermediate (also referred to as moderate) (15.6-31.3 μM), or low (also referred to as 
poor) (62.5-≥500 μM) antibacterial activity against the bacterial strains tested. It is important 
to note that these MIC value ranges are used from here on to qualitatively described all 
compounds tested, including the positive controls.
Overall, when analyzing the MIC data obtained against the Gram-positive bacterial strains 
(strains A-D), we note that most of the novel bis(N-amidinohydrazones) (3A,B, 4C,D, 4F) 
and N-(amidino)-N'-aryl-bishydrazones (7Aa-Ad, and 7Af-Ag) showed excellent 
antibacterial activity against Listeria monocytogenes ATCC 19115 (strain B, Lmo) (MIC 
<0.5-7.8 μM), methicillin-resistant Staphylococcus aureus (strain C, MRSA) (MIC = 1.0-7.8 
μM), and vancomycin-resistant enterococcus (strain D, VRE) (MIC = 1.0-7.8 μM). All of the 
novel compounds displayed poor activity against Bacillus subtilis 168 (strain A, Bsu), with 
the exception of compound 4F, which displayed excellent activity (MIC = 7.8 μM) against 
this strain. Likewise, compound 7Ae exhibited excellent antibacterial activity against L. 
monocytogenes ATCC 19115 (strain B, Lmo; MIC = 7.8 μM) and VRE (strain D; MIC = 
2.0-3.9 μM), but only moderate antibacterial activity against B. subtilis 168 (strain A, Bsu; 
MIC = 31.3 μM) and MRSA (strain C; MIC = 15.6 μM), respectively. In general, 
compounds 4A, 4E (except against strain D, VRE), 4G, 4H, and 8Aa (except against strain 
D) showed poor antibacterial activity (MIC = 62.5-≥500 μM) against all four Gram-positive 
bacterial strains tested. Overall, compound 4F was the most active against Gram-positive 
bacteria.
On the other hand, the majority of the novel compounds remained inactive against most of 
the Gram-negative bacterial strains that we tested with MIC values ranging from 62.5->500 
μM. As one of several exceptions, compound 4A exhibited excellent activity against P. 
aeruginosa ATCC 27853 (strain I, Pae; MIC = 2.0 μM) and moderate activity against 
Klebsiella pneumoniae ATCC 27736 (strain H, Kpn; MIC = 15.6 μM). Similarly, compound 
4F also displayed excellent antibacterial activities against Pae strain I (MIC = 1.0-2.0 μM) 
and S. enterica ATCC 14028 (strain J, Sen; MIC = 3.9 μM), as well as moderate to low 
activity against Kpn strain H (MIC = 31.3-62.5 μM). Additionally, 7Ae showed only 
moderate antibacterial activities against Kpn strain H (MIC = 15.6-31.3 μM), strain I (MIC 
= 31.3-62.5 μM), and Sen strain J (MIC = 15.6 μM). Compounds 3B, 4C-D, 4F, 7Aa-Ad, 
and 7Af-Ag exhibited excellent antibacterial activity (MIC = 1.0-3.9 μM) against M. 
smegmatis MC2-155 (strain K, Msm), whereas compounds 4H and 7Ae showed only 
moderate activity (MIC = 15.6-31.3 μM) and compounds 3A, 4A, 4E, 4G, and 8Aa showed 
low activity (MIC = 125->500 μM) against this mycobacterial strain. It is noteworthy that 
when compared to clinically relevant antibacterial drugs, such as AMK (MIC = 3.9-125 
μM), AMP (MIC ≥250 μM), and OFX (MIC ≤0.5-31.3 μM), the novel compounds showed 
either superior or comparable antibacterial activity against all bacterial strains tested.
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2.4. Antifungal activity
Having established the antibacterial activity profile of the novel bis(N-amidinohydrazones) 
and N-(amidino)-N'-arylbishydrazones, we next determined their antifungal activity against 
a panel of seven Candida albicans strains using a concentration range of 0.5-31.3 μg/mL 
(Table 2). We used the common antifungal agent amphotericin B (AmB) as a positive 
control testing in the same concentration range of 0.5-31.3 μg/mL. For antifungal activity, 
we use the following descriptors: excellent (MIC = 0.5-3.9 μg/mL), moderate (MIC = 
7.8-15.6 μg/mL), and poor (MIC = 31.3 μg/mL). We found that compounds 3B, 4F, 7Aa, 
7Ab, and 7Af exhibited excellent antifungal activities against all fungal strains tested (MIC 
= 1.0-3.9 μg/mL), with 4F being overall the most active. The only exception to the 
aforementioned statement was 7Af, which displayed only moderate activity against C. 
albicans ATCC 90819 (MIC = 7.8 μg/mL). Similarly, compound 4A also displayed excellent 
antifungal activities (MIC = 2.0-3.9 μg/mL) against most strains, except against C. albicans 
ATCC 1003 (MIC = 7.8 μg/mL) and C. albicans ATCC 1237 (MIC = 31.3 μg/mL). 
Compounds 7Ad, 7Ae, 7Ag, and 8Aa showed only moderate fungal growth inhibition (MIC 
= 7.8-15.6 μg/mL) against the majority of the fungal strains, with the exception of C. 
albicans ATCC 64124 (MIC = 31.3 μg/mL for 7Ae, 7Ag, and 8Aa), C. albicans ATCC 
90819 (MIC = 31.3 μg/mL for 7Ag), C. albicans ATCC 1003 (MIC = 3.9 μg/mL for 7Ad) 
and C. albicans ATCC 2310 (MIC = 3.9 μg/mL for 7Ad). Compounds 7Ac also exhibited 
excellent growth inhibition against most of the fungal strains tested, except against C. 
albicans ATCC 10231 (moderate activity, MIC = 7.8 μg/mL) and C. albicans ATCC 64124 
(poor activity, MIC = 31.3 μg/mL). Just as observed against all bacterial strains, compounds 
4G and 4H displayed no activity (MIC ≥31.3 μg/mL) against all fungal strains tested. It is 
important to emphasize that most of our bis(N-amidinohydrazones) and N-(amidino)-N'-
aryl-bishydrazones displayed either superior or comparable antifungal activities against the 
majority of the fungal strains tested, when compared to the clinically-relevant antifungal 
agent, AmB (MIC = 2.0-3.9 μg/mL).
2.5. SAR analysis
Using the antibacterial and antifungal results presented above (Tables 1 and 2), we addressed 
the eight apriori questions posed:
(i) Are linkers comprised of only one aromatic ring sufficient to confer 
antimicrobial activity? We concluded that bis(N-amidinohydrazones) with 
linkers comprised of a single phenyl ring, regardless of its substitution pattern 
(para or meta, as in compounds 4G and 4H, respectively), displayed 
insufficient activity as antimicrobial agents to warrant further study of their 
antibacterial or antifungal activity.
(ii) Is the presence of methyl groups on the carbons alpha to the linker beneficial 
for antimicrobial activity? Comparing the MIC values of compounds 3A and 
4A as well as 7Aa and 8Aa, which only differ by the absence or presence of a 
methyl group on the carbons alpha to the phenyl rings, led us to conclude that 
the methyl group was detrimental to the antibacterial activity of these 
compounds. However, the presence of the methyl group appeared beneficial in 
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terms of antifungal activity. Compound 4A was overall a much more active 
antifungal agent than compound 3A.
(iii) How does the substitution pattern of the biphenyl linker affect antimicrobial 
activity? When evaluating compounds 3A and 3B, the antibacterial MIC values 
were similar in all cases, except against strain K where the MIC value for 
compound 3B (MIC = 1 μM) was 500 times lower than that for compound 3A 
(MIC >500 μM). From these data, we deduced that the substitution pattern of 
the biphenyl linker had minimal effect on antibacterial activity. However, we 
found the substitution pattern of the biphenyl linker to have a substantial effect 
on antifungal activity. For example, compound 3B was a much more active 
antifungal agent than compound 3A.
(iv) How does the length of the flexible linear alkyl spacer between the two phenyl 
rings affect antimicrobial activity? When comparing the MIC values of 
compounds 4A, 4C, and 4D, again we observed opposing trends in 
antibacterial and antifungal activities. Longer flexible alkyl linkers between the 
two phenyl rings correlated with a decrease in antibacterial MIC values, but 
correlated with an increase in antifungal MIC values.
(v) Is the introduction of rigidity in the linker beneficial for antimicrobial activity? 
By contrasting the MIC value profile of compound 4C containing a flexible 
linker to that of compound 4F containing a rigid linker, we concluded that 
introducing rigidity in the linker was overall beneficial for antimicrobial 
activity.
(vi) Is the presence of an oxygen atom in the linker beneficial for antimicrobial 
activity? A comparison of the MIC value profiles of compounds 4C and 4E 
indicated that replacing the methylene bridging the two phenyl groups of the 
linker by an oxygen atom had no effect on antifungal activity, but was 
detrimental to antibacterial activity.
(vii) How does the identity of the substituent, when located at the same position on 
the aryl ring of the side chain, affect antimicrobial activity? By comparing 
compounds 7Aa-7Ag, we observed that the nature of the substituent in the 
ortho position of the mono-substituted aryl group of compounds 7Aa and 7Ab 
did not affect antibacterial or antifungal activity, whereas the nature of the 
substituent in the para position of the mono-substituted aryl group of 
compounds 7Ac-7Ae had opposing effects on antibacterial (CN > halogen) and 
antifungal (halogen > CN) activity. We also observed that the o,p-difluorinated 
and o,p-dichlorinated aryl moieties of compounds 7Af and 7Ag had similar 
overall antibacterial activity, but different antifungal activity, in which the o,p-
difluorinated group possessed improved antifungal activity.
(viii) How does the substitution pattern of the aryl ring (ortho versus para-
monosubstituted versus ortho,para-disubstituted) affect antimicrobial activity? 
Finally, comparison of the activity resulting from different chlorination 
patterns in compounds 7Aa (ortho), 7Ad (para), and 7Ag (o,p-diCl), revealed 
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minimal effects on antibacterial activity, but substantial effects on antifungal 
activity. The o-Cl N-(amidino)-N'-aryl-bishydrazone was superior to the p-Cl 
analogue, which in turn was much better than o,p-diCl analogue. In summary, 
the similarity and differences in the trends observed in this promising, 
preliminary SAR will be used to lay the foundation for the future discovery of 
compounds capable of selectively targeting either bacteria or fungi.
2.6. Development of bacterial and fungal resistance studies
The emergence of antibiotic resistance by microbes is an inevitable process; however, the 
frequency at which resistance develops varies from one antibiotic to another. It is critical to 
assess the ability of new antimicrobials to evade, as long as possible, the development of 
bacterial and fungal resistance early in the drug discovery process. To establish if the bis(N-
amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones evade resistance in bacteria, we 
first performed a multi-step resistance selection experiment with compounds 4D, 4F, and 
7Aa as well as with AMK as a reference drug against four bacterial strains (Figure 1). L. 
monocytogenes ATCC 19115 (strain B, Lmo), MRSA (strain C), VRE (strain D), and P. 
aeruginosa ATCC 27853 (strain I, Pae) were exposed to sub-inhibitory concentrations of 
compounds 4D, 4F, 7Aa, and AMK, and were sub-cultured for 15 serial passages to 
determine if an increase in MIC values occurred for each compound against the strains 
tested. L. monocytogenes ATCC 19115 (strain B, Lmo), MRSA (strain C), VRE (strain D), 
and P. aeruginosa ATCC 27853 (strain I, Pae) did not develop resistance to compound 4F,as 
demonstrated by the one-fold increase in MIC values after 15 serial passages. Likewise, 
strains B (Lmo) and D (VRE) did not develop resistance to compound 7Aa, but strains C 
(MRSA) and I (Pae) developed resistance to this compound after twelve serial passages. In 
contrast, we observed the rapid development of resistance to compound 4D in strains C 
(MRSA) and D (VRE)with a 16-fold increase in MIC values after fifteen serial passages. 
This development of resistance against compound 4D was observed also in strains B (Lmo) 
and I (Pae), where increases in relative MIC values by 8- and 4-folds, respectively, were 
observed after 15 passages. Interestingly, in strains D (VRE) and I (Pae), resistance to the 
control antibiotic, AMK, was observed also after 3 and 5 passages, respectively; whereas in 
strains C (MRSA) and B (Lmo), resistance developed after 12 and 15 passages, respectively. 
Overall, these results indicate that there is a low probability of emergence of resistance to 
these promising novel biscationic compounds 4D, 4F, and 7Aa.
We next investigated the development of drug resistance in C. albicans ATCC 10231 to our 
best antifungal compounds 7Aa and 4F, and we found that C. albicans ATCC 10231 did not 
to develop drug resistance to either 7Aa or 4F, despite repeated treatments with sub-MIC 
drug concentrations. Only a slight 2-fold shift in MIC values was observed after 13 
passages. These results also suggest the low probability of onset of drug resistance by fungi 
to these novel compounds.
2.7. Measurement of ROS induction in fungal cells
Various antifungal drugs, such as AmB and miconazole, as well as novel antifungal agents, 
were shown to mediate their inhibitory effect by inducing intracellular ROS production.30-32 
Universally, eukaryotic cells produce basal amount of ROS in mitochondria as a byproduct 
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of cellular metabolism. In response, the cellular enzymatic antioxidants, including 
superoxide dismutase and glutathione peroxidase, scavenge ROS in cells. However, 
overproduction of deleterious ROS perturbs the delicate, intracellular equilibrium between 
ROS production and scavenging, and the result is cellular damage.
In order to investigate the ability of compounds 4F and 7Aa to alter ROS production in C. 
albicans ATCC 10231 (strain A), we performed a fluorescent-based assay using a 2',7'-
dichlorodihydrofluorescein diacetate (DCFH-DA) dye.33 We found that treatment of C. 
albicans ATCC 10231 (strain A) with compounds 4F and 7Aa at their 1× and 2× MIC values 
increased intracellular ROS production in this fungal strain (Figure 2). As expected, the 
H2O2 positive control (at 1 mM) also induced ROS production in yeast cell, whereas no 
ROS induction was observed with untreated yeast cells (negative control). Although it 
remains to be determined if ROS production is critical for growth inhibition and death of 
yeast cells, these results suggest one direction for future mechanistic exploration, which is 
outside of the scope of the current proof-of-principle exploration for the first generations of 
bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones as antimicrobials.
2.8. Cytotoxicity
Another important aspect to consider during the development of antimicrobial agents is their 
potential toxicity towards mammalian cells. Having established the potent antimicrobial 
activities of the novel bis(N-amidinohydrazones) and N-(amidinohydrazones)-N'-aryl-
bishydrazones against bacteria and fungi, we determined the toxicity profile of these 
compounds against two mammalian cell lines (A549 and BEAS-2B; Figure 3) and measure 
the IC50 values for these compounds (Table 3). The majority of the novel compounds 
showed concentration-dependent toxicity with IC50 values of 1.7-6.7 μg/mL. Compounds 
3B, 7Ac, 7Ad, and 7Af, with excellent antibacterial MIC values of <0.4-3.3 μg/mL, 
displayed IC50 values of 4.4-13.9 μg/mL against both mammalian cell lines. It is important 
to note that compounds 7Ac and 7Af also displayed excellent antifungal MIC values, 
indicating that these compounds are important leads for future evaluation.
2.9. hERG inhibition assay
The hERG encodes a voltage gated potassium channel that plays an essential role in 
regulating hearth rhythm.34 Inhibition of the hERG channel disrupts the heart rhythm and 
may lead to cardiac death. Recently, drugs (e.g., terfendadine and cisapride) were withdrawn 
from the market due to their interaction with the hERG channel.35 Currently, the U.S. Food 
and Drug Administration (FDA) and the European Medicines Agency (EMA) require 
evaluation at hERG for drug candidates.
We performed a [3H]-dofetilide competition binding assay using HEK-293 cell membranes 
stably expressing the hERG channel to evaluate the activity of our most potent bis(N-
amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones at hERG (Figure 4). 
Compounds exhibiting IC50 values of >10 μM are considered to have low affinity for the 
hERG channel. Compounds displaying IC50 values in the range of 1-10 μM are considered 
to have moderate affinity, whereas compounds exhibiting IC50 values of <1 μM are 
considered to have high affinity for the hERG channel.36 The majority of the novel 
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compounds displayed IC50 values within the acceptable range of 1-10 μM (Figure 4). 
Although compound 7Ab displayed excellent antifungal activities (2-3.9 μg/mL), it 
exhibited in vitro mammalian cell toxicity and was found to potently interact with the hERG 
channel (IC50 = 0.44 ± 0.10 μM), suggesting that the o-bromophenyl substituent is an 
unfavorable structural feature. However, the p-fluorophenyl and the 2,4-difluorophenyl 
groups in compounds 7Ac and 7Af displayed only moderate interaction with hERG (IC50 = 
3.29 ± 0.63 μM and 2.24 ± 0.70 μM, respectively). Strikingly, both of these compounds 
displayed excellent antifungal activities and also exerted low mammalian cell toxicity. 
Similarly, compounds 4F and 7Aa displayed moderate affinity for hERG (IC50 = 1.12 ± 0.32 
μM and 1.14 ± 0.27 μM, respectively); however, they displayed some toxicity against 
mammalian cells. Therefore, we concluded that compounds 7Ac and 7Af are the most 
promising N-(amidino)-N'-aryl-bishydrazone compounds.
3. Conclusions
In summary, we discovered nine bis(N-amidinohydrazones) and eight N-(amidino)-N'-aryl-
bishydrazones as first-generation antibacterial and antifungal agents. These compounds 
displayed low potential for the development of resistance and were found to induce ROS 
production in a C. albicans strain. They also were found to display reasonable toxicity 
profiles against two mammalian cell lines as well as acceptable levels of interaction with 
hERG channels. However, as these compounds display both antibacterial and antifungal 
activity, it is possible that they aim at a target shared by prokaryotes and eukaryotes and 
potentially display lower selectivity. However, in light of our SAR study, we conclude that 
compounds 4F, 7Ac, and 7Af, which showed the most promise, warrant further 
optimization. Such studies are currently underway in our laboratories.
4. Experimental section / Supplementary material
Refer to Web version on PubMed Central for supplementary material.
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Scheme 1. 
Synthetic scheme for the preparation of A. the bis(N-amidinohydrazones) and B. N-
(amidino)-N'-aryl-bishydrazones.
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Figure 1. 
Changes in MIC values of L. monocytogenes ATCC 19115 (strain B), MRSA (strain C), 
VRE (strain D), and P. aeruginosa ATCC 27853 (strain I) treated with AMK (green), 7Aa 
(purple), 4F (blue), 4D (orange), as well as C. albicans ATCC 10231 treated with AmB 
(yellow), 7Aa (purple), and 4F (blue) over 15 cycles. Numbers above the bars represent the 
passage when either bacterial or fungal cells developed resistance.
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Figure 2. 
Effect of compounds 4F and 7Aa on intracellular ROS production by C. albicans ATCC 
10231. Yeast cells were treated in the absence of drug (negative control), 1 mM of H2O2 
(positive control), or 4F and 7Aa, at 1× and 2× respective MIC values for 1 h at 35 °C. After 
staining with DCFH-DA (20 μg/mL), the samples were analyzed using a Zeiss Axovert 
200M fluorescence microscope.
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Figure 3. 
Mammalian cell cytotoxicity of selected bis(N-amidinohydrazones) and N-(amidino)-N'-
aryl-bishydrazones, as well as AmB (as a control) against A. A549 cell line and B. 
BEAS-2B cell line.
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Figure 4. 
IC50 curves for hERG interaction by representative bis(N-amidinohydrazones) and N-
(amidino)-N'-aryl-bishydrazones along with a table (bottom right) summarizing these IC50 
values.
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Table 2
MIC values in μg/mL
a
 and (μM) for compounds 3A,B, 4A,C-H, 7Aa-Ag, and 8Aa against various C. albicans 
strains.
C. albicans ATCC strain #
Cpd
1003
a
1237
b
2310
c
2876
c
10231
b
64124
b
90819
b
AmB 3.9 (4.2) 3.9 (4.2) 3.9 (4.2) 3.9 (4.2) 3.9 (4.2) 2.0-3.9 (2.1-4.2) 2.0 (2.1)
3A 7.8 (19.7) 15.6 (39.5) >31.3 (>79.2) 7.8 (19.7) 15.6 (39.5) >31.3 (>79.2) >31.3 (>79.2)
3B 3.9 (9.9) 3.9 (9.9) 3.9 (9.9) 3.9 (9.9) 3.9 (9.9) 3.9 (9.9) 3.9 (9.9)
4A 7.8 (18.4) >31.3 (>73.9) 3.9 (9.2) 2.0 (4.7) 2.0-3.9 (4.7-9.2) 2.0 (4.7) 3.9 (9.2)
4C 7.8 (17.8) 7.8 (17.8) 7.8 (17.8) 3.9 (8.9) 7.8 (17.8) 7.8 (17.8) 7.8 (17.8)
4D 15.6 (34.6) 15.6 (34.6) 31.3 (69.3) 3.9 (8.6) 7.8 (17.3) >31.3 (>69.3) 7.8 (17.3)
4E 7.8 (17.8) 7.8 (17.8) 7.8 (17.8) 3.9 (8.9) 7.8 (17.8) 7.8 (17.8) 7.8 (17.8)
4F 1.0 (2.3) 2.0 (4.6) 1.0 (2.3) 1.0 (2.3) 1.0-2.0 (2.3-4.6) 1.0 (2.3) 2.0 (4.6)
4G >31.3 (>90.1) >31.3 (>90.1) >31.3 (>90.1) >31.3 (>90.1) >31.3 (>90.1) 31.3 (90.1) >31.3 (>90.1)
4H >31.3 (>90.1) 31.3 (90.1) 31.3 (90.1) 7.8 (22.5) >31.3 (>90.1) >31.3 (>90.1) >31.3 (>90.1)
7Aa 2.0 (4.6) 3.9 (9.2) 2.0 (4.6) 2.0 (4.6) 2.0 (4.6) 3.9 (9.2) 2.0 (4.6)
7Ab 2.0 (4.1) 3.9 (8.3) 3.9 (8.3) 3.9 (8.3) 2.0 (4.1) 3.9 (8.3) 3.9 (8.3)
7Ac 2.0 (4.7) 7.8 (19.0) 3.9 (9.5) 3.9 (9.5) 7.8 (19.0) 31.3 (76.2) 3.9 (9.5)
7Ad 3.9 (9.1) 15.6 (36.5) 3.9 (9.1) 7.8 (18.3) 7.8 (18.3) 15.6 (36.5) 7.8 (18.3)
7Ae 7.8 (18.7) 15.6 (37.3) 15.6 (37.3) 15.6 (37.3) 15.6 (37.3) 31.3 (74.9) 15.6 (37.3)
7Af 2.0 (4.5) 3.9 (9.1) 3.9 (9.1) 3.9 (9.1) 1.0 (2.3) 3.9 (9.1) 7.8 (18.2)
7Ag 7.8 (16.8) 15.6 (33.8) 7.8 (16.8) 15.6 (33.8) 7.8 (16.8) 31.3 (67.8) 31.3 (67.8)
8Aa 15.6 (34.3) 15.6 (34.3) 15.6 (34.3) 15.6 (34.3) 15.6 (34.3) 31.3 (68.7) 15.6 (34.3)
Control antifungal agent: AmB = amphotericin B.
a
These antifungal MIC values were determined originally in μg/mL using a range of 0.5 to 31.3 μg/mL. The values in μM into parentheses are 
presented for comparison with the antibacterial MIC values, which were determined originally in μM.
b
Indicates strains that are resistant to FLC, ITC, and VOR according to ATCC.
c
Indicates strains that are susceptible to FLC, ITC, and VOR according to ATCC.
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Table 3
The cytotoxicity (IC50, μg/mL) of selected bis(N-amidinohydrazones) and N-(amidino)-N′-aryl-bishydrazones 
against A549 and BEAS-2B cell lines. Values are presented as mean ± SDEV.
Mammalian cell line
Cpd A549 BEAS-2B
AmB 18.2 ± 4.5 17.7 ± 6.4
3A 6.6 ± 1.7 3.0 ± 0.7
3B 13.9 ± 4.1 5.7 ± 1.8
4A 6.3 ± 2.2 1.7 ± 0.5
4C 4.3 ± 1.3 2.9 ± 0.9
4D 2.9 ± 0.9 1.8 ± 0.6
4E 3.9 ± 0.9 2.9 ± 0.9
4F 2.5 ± 1.4 1.8 ± 0.6
4H 31.2 ± 7.2 33.0 ± 4.6
7Aa 2.8 ± 0.9 2.3 ± 1.0
7Ab 6.7 ± 2.3 3.4 ± 1.3
7Ac 4.4 ± 1.4 6.0 ± 1.2
7Ad 4.9 ± 1.1 6.0 ± 1.1
7Ae 4.2 ± 1.4 1.9 ± 0.8
7Af 4.8 ± 1.3 5.8 ± 1.2
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